Soft multifocal lenses show promise as a management tool for accommodation and vergence disorders in patients without presbyopia.
The VEGA-3 Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia is also enrolling patients. Top-line results are expected in the first half of 2025. The ...
A live audio webcast of the Piper Sandler Healthcare Conference fireside chat can be accessed here and on the LENZ ...
CSF-1 consistently reduces pupil size with an overall gain in near and distance vision when administered to patients with presbyopia. Pilocarpine is a cholinergic muscarinic receptor agonist that ...
Comfort was the name of the game when OT spoke with contact lens manufacturers and suppliers about recent trends and launches ...
Aceclidine, a pupil-selective miotic, is well tolerated and significantly improves near vision in patients with presbyopia, according to research presented at the American Academy ...
Healthcare Asia on MSN4d
Global myopia and presbyopia treatment market to grow by $9.76b by 2028It is driven by the rising prevalence of these vision conditions. The global myopia and presbyopia treatment market is set to ...
The "Myopia and Presbyopia Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's ...
In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...
CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia Cash ...
The FDA has accepted for review the New Drug Application for LNZ100 (aceclidine 1.75% ophthalmic solution) for the treatment of presbyopia.
Tom Frinzi, President and CEO of STAAR Surgical, states, "Lucy Bronze is a champion on the football pitch, and we are proud ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback